News

Verve Therapeutics Grants Equity Awards to New Employees

Verve Therapeutics Grants Equity Awards to New Employees

Verve Therapeutics Grants Equity Awards to New Employees

BOSTON — Verve Therapeutics, a pioneering clinical-stage biotechnology company, recently announced an important step in its growth by granting equity awards to five new employees. This move comes as part of the company’s 2024 Inducement Stock Incentive Plan, which aims to attract and retain top talent in line with Nasdaq Listing Rule 5635(c)(4).

On September 30, 2024, the company awarded a total of 33,280 restricted stock units (RSUs) to these newcomers. This strategic decision reflects Verve's commitment to fostering a strong workforce while aligning the interests of its employees with the company's long-term goals. The RSUs will vest in equal annual installments over the first four anniversaries of October 1, 2024, conditional upon the continued service of each employee on each vesting date.

About Verve Therapeutics

Verve Therapeutics, Inc. (Nasdaq: VERV) specializes in developing transformative genetic medicines aimed at addressing cardiovascular disease. The innovative approaches undertaken by the company have the potential to shift treatment paradigms from chronic management to single-course gene editing therapies. Verve's lead programs—VERVE-101, VERVE-102, and VERVE-201—are meticulously crafted to target well-established genes linked to lowering low-density lipoprotein cholesterol (LDL-C), a primary contributor to atherosclerotic cardiovascular disease (ASCVD).

Key Programs and Their Impact

VERVE-101 and VERVE-102 focus on effectively turning off the PCSK9 gene located in the liver. These interventions are intended for patients suffering from heterozygous familial hypercholesterolemia (HeFH) and those with established ASCVD who struggle with high LDL-C levels. By tackling this genetic component, the company aims to provide a vital solution that could lead to significant health improvements for many patients.

Groundbreaking Research and Development

Meanwhile, VERVE-201 aims to permanently disable the ANGPTL3 gene in the liver, targeting patients with refractory hypercholesterolemia—those who continue to experience high LDL-C despite adhering to maximally tolerated standard care therapies—as well as addressing homozygous familial hypercholesterolemia (HoFH). Verve Therapeutics is poised to make a remarkable difference in the lives of individuals facing daunting cardiovascular challenges through these innovative treatments.

Commitment to Transparency and Communication

As part of its corporate ethos, Verve Therapeutics maintains an open line of communication with investors and the media. For those interested in following the company’s journey toward revolutionizing the treatment of cardiovascular diseases, contact details for investor inquiries can be found below. Verve's proactive approach to sharing information reflects its belief in transparency and trust in the investment community.

Contact Information

For investor relations, connect with Jen Robinson via email at jrobinson@vervetx.com. For media inquiries, Ashlea Kosikowski is available at ashlea@1abmedia.com.

Frequently Asked Questions

What recent developments has Verve Therapeutics announced?

Verve Therapeutics has announced equity awards to five new employees under its 2024 Inducement Stock Incentive Plan, aimed at enhancing its workforce.

What are the main focuses of Verve Therapeutics' research?

The main research activities include developing genetic therapies targeting genetic factors that lead to cardiovascular diseases, particularly focusing on high LDL cholesterol levels.

How many restricted stock units were awarded to new employees?

A total of 33,280 restricted stock units (RSUs) were awarded, with vesting scheduled over four annual installments.

What are the lead therapies being developed by Verve Therapeutics?

Verve Therapeutics is focusing on programs like VERVE-101, VERVE-102, and VERVE-201, which target the PCSK9 and ANGPTL3 genes.

How does Verve Therapeutics plan to transform cardiovascular treatment?

By developing gene editing therapies, Verve aims to shift the treatment of cardiovascular diseases from chronic management to potentially single-course solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovative Trial Targets Drug Resistance in Lung Cancer

Updated Category News Views 77

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Continue Reading
Right College Fit Crucial for Graduation Rates

Updated Category News Views 60

Navigating College Choices: More Than Just a Hunch When it comes to picking the right college, a lot of folks think it's like shooting in the dark—it's more than just a blind dart throw at a life map. According to a new report from the College Board, aligning with the right academic institution isn't merely a nice-to-have deal; it fundamentally shifts the odds in favor...

Continue Reading
Abbe Lane's Estate Auction: Glamour Up for Grabs

Updated Category News Views 72

Glamour from the Mid-Century Comes to the Auction Block In a world obsessed with the flavor of the month, a collection that truly turns heads by sailing in on a wave of genuine mid-century splendor isn't something you stumble upon every day. John Moran Auctioneers has the privilege to crack open the vault on the Estate of Abbe Lane, a name that once rolled off tongues...

Continue Reading
J.H. Strain & Sons' Asset Sale Seals a New Era

Updated Category News Views 59

Texan Legacy Bows Out of the Asphalt Game Here's a fresh chapter in the world of road construction that'll have folks in the industry doing a double-take. Elder Bray & Bankler, a bigwig among corporate law circles, has been guiding this tale. They've shepherded J.H. Strain & Sons through selling off its asphalt manufacturing and construction assets to none other than...

Continue Reading
Navigate360 Data Breach Concerns: Legal Insights

Updated Category News Views 55

No Safety in a Storm: Navigate360's Data Breach Fiasco When you think of data breaches, you often envision some shady hacker in a hoodie, but here we are with Navigate360 losing control of a massive chunk of sensitive data involving school safety tips. You'd hope companies with serious access to personal information are better at keeping secrets, right? Yet, here we are,...

Continue Reading
Sinopec's Bold African Moves: Sustainability and WE17

Updated Category News Views 106

A Bold African Initiative Alright, folks, let's get into the nitty-gritty of Sinopec's game plan in Africa. There's something to be said about a behemoth like Sinopec rolling out a sustainability report with real substance. We're looking at 33 projects across 16 countries, $5.7 billion in investments. Now, that's not just pocket change. Economic Muscle and Environmental...

Continue Reading
A&S Construction Creates Winning Culture in Louisville

Updated Category News Views 31

A&S Construction's Winning Formula: Culture Over Growth Look, in the dog-eat-dog world of construction, what really sets you apart isn't just how many roofs you stack up or the number of renovations you churn through. It's how you treat your people. And A&S Construction of Louisville gets that—ranking No. 6 in its category on the 2026 Best Places to Work list, all while...

Continue Reading
SELCO and Numerica Unite: A Merger That's All Heart

Updated Category News Views 67

Big Merger in Credit Union World: SELCO and Numerica Sometimes, it ain't all about dollars and cents. That's the vibe I'm picking up from this merger of equals between SELCO Community and Numerica Credit Unions. This isn't a Wall Street hustle, it's hometown hustle—where the biggest reward isn't just a fat line at the bottom but seeing your community thrive. The Vision...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Fed Holds Steady, But CD Rates Climb: Savers' Edge

Updated Category News Views 121

The Fed Sits Tight, But CD Rates Surge Isn't it a kicker when the Fed holds rates steady, yet the CD market is buzzing like a crowded trading floor on a bull run? We've seen the Federal Reserve hold its ground without budging interest rates, keeping everyone guessing while inflation's still a shadow in the corner. But the star of the show here isn't the Fed's poker...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover 'The Sanctuary' at RISE Festival with Tao Group

Updated Category News Views 295

Introducing 'The Sanctuary' at RISE Festival Step into an elevated realm of excitement as the RISE Festival announces a spectacular addition for its 10th anniversary: 'The Sanctuary'. This unique collaboration with Tao Group Hospitality marks a new chapter in festival experiences by combining luxury with world-class entertainment. What to Expect from The Sanctuary The...

Continue Reading
Empowering Careers: Workcred's New Pathways Initiative

Updated Category News Views 153

Empowering Career Pathways with Workcred's New Initiative ECMC Foundation-Funded Initiative Produces Materials to Support Skills-Based Career Pathways As the job market increasingly favors skills-based hiring, educational institutions are working diligently to enhance career readiness among students. This is where Workcred steps in with a groundbreaking resource...

Continue Reading
Global Manufacturing Demand Weakens as Supply Chains Adjust

Updated Category News Views 169

Global Manufacturing Dynamics in 2026 The latest insights from the GEP Global Supply Chain Volatility Index reveal a significant shift in manufacturing demand across the globe as we approach 2026. While spare capacity persists in various regions, manufacturing activity in North America is facing notable challenges, marking the steepest decline in input demand. North...

Continue Reading
Kaléo’s Rapid Opioid Countermeasure System Honored with Award

Updated Category News Views 206

Kaléo Receives Recognition for Innovative Opioid Antidote Kaléo has achieved a significant milestone in its mission to address urgent public health needs by receiving the Prototype Innovation Award from the Medical CBRN Defense Consortium (MCDC). This prestigious recognition is for the development of its Rapid Opioid Countermeasure System (ROCS), specifically designed...

Continue Reading
Fortify Restoration Launches Following Growth and Recapitalization

Updated Category News Views 184

New Developments in the Structural Restoration Industry In an exciting turn of events, Transworld M&A Advisors, under the leadership of Managing Director Peter Berg, has announced the recapitalization of GC Restoration, a pivotal move that sets the foundation for a new venture named Fortify Restoration. This fresh platform aims to fortify structural restoration services...

Continue Reading